GlassScriptPhysician profile
Thomas J Kenney
NPI 1386782902
$568.70
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $203.40 | 2019 | |
| Astellas Pharma US INC | $69.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.66 | 2019 | |
| Pfizer INC. | $53.28 | 2019 | |
| Janssen Biotech, INC. | $48.48 | 2019 | |
| Gilead Sciences, INC. | $28.62 | 2019 | |
| Verastem, INC. | $21.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.13 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.68 | 2019 | |
| Daiichi Sankyo INC. | $16.35 | 2019 | |
| Seagen INC. | $11.72 | 2019 | |
| Merck Sharp & Dohme LLC | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kenney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.